Vaccine for Japanese encephalitis

Novartis Vaccines has launched Ixiaro for active immunisation of adults against Japanese encephalitis.

Ixiaro, the only vaccine licensed for Japanese encephalitis, is a purified formalin-inactivated whole-virus, cultivated in Vero-cells. Ixiaro should be considered for use in individuals at risk of exposure to Japanese encephalitis through travel or in the course of their occupation.


A study looked at the seroconversion in three dosing schedules: 6 microgram injection on days 0 and 28; 6 microgram injection on day 0; and 12 microgram on day 0. Those who did not receive two doses of the vaccine received placebo on day 28. 97.3% of patients on the two-dose schedule reached seroconversion on day 56 compared to 25.6% in the single 6 microgram group and 41.2% in the single 12 microgram group.1

Another study compared the use of Ixiaro with a previously licensed vaccine to test its immunogenicity; 98% seroconversion was seen in patients who received Ixiario compared to 95% seen in the previously licensed vaccine group.2 There were no serious adverse effects seem in either group with the most common adverse effects including headache, flu-like illness, myalgia and fatigue.2

View Ixiario drug record


  1. Schuller E et al. Vaccine 2008; 10.1016
  2. Tauber  E et al. Lancet 2007; 370: 1847-53

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more